Novartis International AG http://www.novartis.com Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Novartis provides progress-update to achieving 77% majority ownership of Alcon 2010-06-30T22:45:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1428790.shtml Novartis launches Prevacid®24HR over-the-counter for full 24-hour frequent heartburn treatment 2009-11-12T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1354451.shtml Basel, November 12, 2009 - Novartis announced the availability of Prevacid®24HR (lansoprazole delayed-release capsules 15 mg/acid reducer) over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn. Prevacid®24HR received US Food and Drug Administration (FDA) approval in May 2009. It is the first and only over-the-counter (OTC) Proton Pump Inhibitor (PPI) for the treatment of frequent heartburn in its original formulation. Novartis receives approval from FDA to market Prevacid®24HR as first and only OTC proton pump inhibitor in original formulation 2009-05-14T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1314777.shtml Basel, Switzerland, May 14, 2009 - Novartis announced today that Prevacid®24HR (lansoprazole delayed-release capsules 15 mg) has been approved by the U.S. Food and Drug Administration (FDA) as the first over-the-counter (OTC) Proton Pump Inhibitor (PPI) for the treatment of frequent heartburn since 2003. Prevacid24HR is expected to be available over-the-counter in 2009. Gestützt auf eine verstärkte Innovationsdynamik erzielt Novartis im zweiten Quartal eine starke finanzielle Performance 2010-07-15T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1431807.shtml